



**3rd Dresden International Symposium  
on Therapeutic Apheresis**  
March 13 – 15, 2014  
**Lipidologische Fortbildung**  
March 14, 2014

Department of Medicine III  
University Hospital Dresden  
Fetscherstraße 74  
01307 Dresden  
Germany

**Advance notice**

## Welcome

Dear colleagues,

This is already the third international symposium on therapeutic apheresis taking place in Dresden.

The aim is to organize a high level international conference on Lipoprotein apheresis and Immunoabsorption for autoimmune diseases. We hope that the lectures by prominent invited speakers will spark lively discussions and complete a comprehensive overview on the potential of apheresis as well as ways to reach therapeutic targets.

A special topic will be the presentation of new drugs for the treatment of hypercholesterolemia which have recently been developed or are already registered.

For this occasion, it is a pleasure to invite you to the beautiful city of Dresden, which, after decades of restoration shines anew these days. In fact, the University Hospital is just 15 minutes away from the very center of the old city. We hope to see you in Dresden.

With best regards,

  
Prof. Ulrich Julius

  
Prof. Bernd Hohenstein



# H.E.L.P.

Just more than  
LDL-Apheresis

**B. BRAUN**  
SHARING EXPERTISE

## Lipoprotein apheresis

Auditorium in the Dean's Building (House 40)

### Thursday, March 13, 2014

- 13.00 - 13.40 **Lipoprotein(a) – what's new?**  
Borge Nordestgaard, Copenhagen
- 13.40 - 14.05 **Screening activities for cardio-metabolic risk characterization**  
Wolfgang Ramlow, Rostock
- 14.05 - 14.25 **Lipoprotein(a) as a risk factor in outpatients**  
Sergey Tselmin, Dresden
- 14.25 - 14.45 **Lipid and lipoprotein(a) levels in patients of a stroke unit**  
Ulf Bodechtel, Dresden
- 14.45 - 15.00 **Effect of niacin on lipoprotein(a) level is dependent on apo(a) phenotypes**  
Nadya Ertemeva, Moscow

#### Break

- 15.30 - 16.00 **Efficacy of chronic lipoprotein apheresis in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease approved according to German reimbursement guidelines – particular results of the prospective observational multicenter study Pro(a)LiFe**  
Reinhard Klingel, Cologne
- 16.00 - 16.30 **Lipoprotein apheresis in patients with refractory angina and raised lipoprotein(a)**  
Tina Kahn, London
- 16.30 - 16.50 **Lipoprotein apheresis in patients with isolated elevated lipoprotein(a) – effects on the incidence of cardiovascular diseases**  
Elisabeth Steinhagen-Thiessen, Berlin
- 16.50 - 17.10 **Influence of lipoprotein apheresis on the lipoprotein(a) levels in the long run**  
Elisa Groß, Dresden
- 17.10 - 17.40 **Do we need a lipoprotein apheresis specific for lipoprotein(a) – the Moscow experience**  
Marat Ezhov, Moscow

#### Break

- 18.00 - 18.30 **Effects of lipoprotein apheresis on PCSK9 levels**  
Ulrich Julius, Dresden
- 18.30 - 19.00 **PCSK9-inhibitors – a new class of lipid-lowering drugs**  
Ionna Gouni-Bertholdt, Cologne

### Friday, March 14, 2014

- 09.00 - 09.30 **Influence of lipoprotein apheresis on the kinetics of lipoproteins**  
Klaus Parhofer, Munich
- 09.30 - 10.00 **Lipoprotein apheresis and cholesterol efflux**  
Tiziana Sampietro, Pisa
- 10.00 - 10.30 **Effect of acute cholesterol lowering on lipoproteins**  
Patrick Moriarty, Kansas
- 10.30 - 10.45 **Effect of lipoprotein apheresis on cytokines – new data**  
Claudia Stefanutti, Rome
- 10.45 - 11.00 **New data on lipidomics in lipoprotein apheresis patients**  
Jürgen Gräßler, Dresden

#### Break

- 11.15 - 11.35 **Dynamics of complement and rheological indicators after the therapy with rheopheresis**  
Milan Blaha, Hradec Kralove
- 11.35 - 11.50 **Rheological effects of lipoprotein apheresis**  
Beate Jäger, Mülheim-Ruhr
- 11.50 - 12.10 **First data from the German-Lipoprotein-Apheresis Registry (GLAR)**  
Volker Schettler, Göttingen
- 12.10 - 12.30 **Actual situation of lipoprotein apheresis in Saxony in 2013**  
Ulrike Emmrich, Dresden
- 12.30 - 12.50 **Detailed description of the cardiovascular situation in patients who have started an apheresis treatment**  
Steffen Schampera, Dresden
- 12.50 - 13.20 **Long-term experience with lipoprotein apheresis**  
Gennadi Konovalov, Moscow

**19.30 Gala Dinner (included)**  
Swissôtel Dresden am Schloss, Schlossstraße 16,  
01067 Dresden, Germany

### Saturday, March 15, 2014

- 09.00 - 09.20 **Lipoprotein(a) – cellular effects**  
Ryuichi Morishita, Osaka
- 09.20 - 09.40 **Klinische Wirksamkeit und Sicherheit der Lipoprotein-apherese: Erfahrungen aus 35.000 Behandlungen**  
Franz Heigl, Kempten
- 09.40 - 10.00 **Lipoprotein apheresis in patients with peripheral occlusive arterial disease**  
Kathrin Enke-Melzer, Berlin
- 10.00 - 10.30 **Lipoprotein apheresis in children**  
Volker Witt, Vienna
- 10.30 - 10.50 **Lipoprotein apheresis in children – the Marburg experience**  
Günter Klaus, Marburg

#### Break

- 11.00 - 11.20 **Managing homozygous FH from cradle to grave?**  
Gilbert Thompson, London
- 11.20 - 11.40 **Pregnancy in homozygous familial hypercholesterolemia – when the things are going well**  
Milan Blaha, Hradec Kralove
- 11.40 - 12.00 **Lomitapide in homozygous FH patients**  
Maurizio Averna, Palermo
- 12.00 - 12.20 **Effect of lipids on cardiovascular autonomic regulation**  
Tjalf Ziemssen, Dresden
- 12.20 - 12.40 **Nebenwirkungen der Lipoprotein-Apherese-Therapie**  
Anja Ramlow, Rostock
- 12.40 - 13.00 **Pflegerische Aspekte der Apherese bei verschiedenen Behandlungsindikationen**  
Ines Schulz-Merkel, Kempten

#### Break

- 13.30 - 13.50 **Konsequenzen aus der steigenden Anzahl von Patienten in einem Apherese-Zentrum**  
Kerstin Johné, Dresden
- 13.50 - 14.10 **HTG in an outpatient department – significance as an atherosclerotic risk factor**  
Moritz Scholz, Dresden
- 14.10 - 14.40 **Severe hyperchylomicronemia and hypertriglyceridemia: why, when and how it is to be treated**  
Claudia Stefanutti, Roma

### Saturday, March 15, 2014

- 14.40 - 15.00 **Effect of lipoprotein apheresis on FABP4 – long-term study**  
Valeria Lamounier-Zepter, Dresden
- 15.00 - 15.20 **Comparison of two intravenous iron preparations in patients treated with lipoprotein apheresis**  
Ulrike Schatz, Dresden
- Break**
- 15.40 - 16.00 **Beyond extracorporeal lipoprotein apheresis – impact on health-related quality of life in lipoproteinapheresis (LA) patients compared to patients with coronary heart disease (CHD) and to patients undergoing hemodialysis treatment (HD)**  
Volker Schettler, Göttingen
- 16.00 - 16.20 **Psychische Situation von Apherese-Patienten im Vergleich zu Hämodialyse-Patienten**  
Eva Stasiewsky, Dresden
- 16.20 - 16.30 **Concluding remarks**  
Ulrich Julius, Dresden

# Immunadsorption

House 19 Room 1.158

Friday, March 14, 2014

- 09.00 - 09.20 **Immunoadsorption before and after renal transplantation**  
Christian Hugo, Dresden
- 09.20 - 09.40 **Acquired Haemophilia: Conventional Treatment vs. Apheresis**  
Heike Zeitler, Bonn
- 09.40 - 10.00 **Plasma exchange vs. immunoadsorption in steroid refractory neuroinflammatory demyelinating diseases**  
Michael Koziol, Göttingen
- 10.00 - 10.20 **Immunoadsorption in autoimmune encephalitis**  
Wolfgang Köhler, Wernsdorf
- 10.20 - 10.40 **Immunoadsorption in multiple sclerosis**  
Bernd Hohenstein, Dresden
- 10.40 - 11.00 **Immunoadsorption in myasthenia gravis**  
Kurt Derfler, Vienna
- 11.00 - 11.20 **Antibodies against AT1-receptor in transplantation (diagnostic, treatment, clinical relevance)**  
Dagmar Barz, Jena
- 
- Break**
- 11.40 - 12.00 **Therapeutic apheresis in pediatric patients with acute CNS inflammatory demyelinating disease**  
Michael Koziol, Göttingen
- 12.00 - 12.20 **Therapie der Präeklampsie mittels sFlt-1-Apherese**  
Holger Stepan, Leipzig
- 12.20 - 12.40 **IA-Pem Study**  
Claudia Günther, Dresden
- 12.40 - 13.00 **Immunoadsorption in thromboangitis obliterans**  
Norbert Weiss, Dresden
- 
- Break**
- 13.40 - 14.00 **Immunoadsorption in Thromboangitis obliterans – new data**  
Peter Klein-Weigel, Berlin
- 14.00 - 14.20 **Immunoadsorption in SLE**  
Kurt Derfler, Vienna
- 14.20 - 14.40 **Immunoadsorption in children**  
Theresa Kwon, Paris

Friday, March 14, 2014

- 14.40 - 15.00 **Targeting suPAR in focal-segmental glomerulosclerosis by apheresis or immunoadsorption – a therapeutic perspective?**  
Christian Morath, Heidelberg
- 15.00 - 15.20 **Immunoadsorption can improve cardiac function in transplant candidates with non-ischemic cardiomyopathy associated with diabetes mellitus**  
Michael Dandel, Berlin
- 15.20 - 15.40 **Immunoadsorption after heart transplantation**  
Nick Banner, Harefield
- 15.40 - 16.00 **The effect of plasma exchange and immunoadsorption on the vaccination status**  
Silke Rummeler, Jena

# Lipidologische Fortbildung

Auditorium in the Dean's Building (House 40)

Friday, March 14, 2014

Diese Veranstaltung wird im Rahmen der strukturierten curriculären Fortbildung Lipidologie DGFF (Lipidologie DGFF®) als Fortbildungsnachweis anerkannt.

Weitere Informationen hierzu sind erhältlich unter [www.lipid-liga.de](http://www.lipid-liga.de), Rubrik "Lipidologie DGFF".



- 14.00 - 14.30 **25 Jahre Lipid-Liga**  
Ulrich Klör, Gießen
- 14.30 - 15.00 **Die aktuelle Rolle der HDL im Rahmen der Atherogenese**  
Klaus Parhofer, München
- 15.00 - 15.30 **Diagnostische und therapeutische Optionen bei Patienten mit hohen Lipoprotein(a)-Spiegeln**  
Elisabeth Steinhagen-Thiessen, Berlin
- 15.30 - 16.00 **Omega-3-Fettsäuren in der Lipidtherapie**  
Ulrich Julius, Dresden
- 16.00 - 16.30 **Praktische Durchführung der medikamentösen lipidsenkenden Pharmakotherapie**  
Sabine Fischer, Dresden
- 16.30 - 17.00 **Neue Entwicklungen in der lipidsenkenden Pharmakotherapie: Mipomersen, Lomitapide, PCSK9-Inhibitoren**  
Heiner Bertholdt, Berlin

## Scientific Program supported by:

- Fresenius Medical Care GmbH
- Kaneka Pharma Europe N.V.
- Miltenyi Biotec GmbH
- B. Braun Avitum AG
- DIAMED Medizintechnik GmbH
- medicap clinic GmbH
- Trommsdorff GmbH & Co. KG Arzneimittel
- MSD SHARP & DOHME GmbH (1500 EUR)
- Sanofi-Aventis Deutschland GmbH
- Vifor Pharma Deutschland GmbH
- Roche Deutschland Holding GmbH
- AMGEN GmbH
- STADA Pharma GmbH
- Abbott Deutschland

Gemäß FSA-Kodex – § 20 Abs. 5 sind die im FSA vereinten Firmen verpflichtet, den Umfang des Sponsorings für Veranstaltungen offenzulegen. Jeweils für Werbemöglichkeiten und Standkosten.

Die Offenlegung erfolgt auch im Internet [www.carus-management.de](http://www.carus-management.de) und während der Veranstaltung.

## How to find us



Overview University Hospital Dresden

**University Hospital Dresden**  
Department of Medicine III  
Fetscherstraße 74  
01307 Dresden

### International Travel

Dresden International airport is approximately 30 minutes from the clinical center and served by regional railway. International trains arrive both at Dresden main station and at Dresden Neustadt with convenient connections to tramway lines.

### Public Transport

The University Hospital is served by tramway lines 6 and 12 (Stop: Augsburger Straße/ Universitätsklinikum) as well as bus lines 64 and 62 (Stop: Universitätsklinikum).

### Car

For fee parking is available at the Fiedlerstraße main entrance parking deck with room for 500 cars.

## Registration

Please register by sending or faxing the attached form to the Carl Gustav Carus Management GmbH.  
[www.carus-management.de](http://www.carus-management.de)

You can also register via E-mail:  
[CGCManagementGmbH@uniklinikum-dresden.de](mailto:CGCManagementGmbH@uniklinikum-dresden.de)

Or write an E-mail to:  
[ulrich.julius@uniklinikum-dresden.de](mailto:ulrich.julius@uniklinikum-dresden.de)

The registration fee for participants is 80 EUR by March 01, 2014 – thereafter the registration fee will be 100 EUR (physicians / scientists in training 40 EUR, students (with ID) 20 EUR).

The Gala Dinner will be included.

We will apply for CME points at the Sächsische Landesärztekammer.

Updated information about the symposium including the scientific program will be provided on the following website:

<http://mk3.uniklinikum-dresden.de/apheresissymposium>

Bank:

Deutsche Kreditbank AG  
Account No.: 11 248 333  
Bank code: 120 300 00

IBAN: DE 71 1203 0000 0011 248 333  
BIC: BYLADEM 1001

### Registration form:

Please send or fax this filled form to the conference agency until February 28, 2014!

Carl Gustav Carus Management GmbH Phone: +49 351-458-4469  
Fetscherstr. 74 Fax: +49 351-458-6323  
01307 Dresden E-Mail: [CGCManagementGmbH@uniklinikum-dresden.de](mailto:CGCManagementGmbH@uniklinikum-dresden.de)

- 3rd Dresden International Symposium on Therapeutic Apheresis  
 Lipidologische Fortbildung  
(Teilnahme kostenfrei / DGFF Lipid-Liga e.V.)

Surname	First Name
Title	
Address	
E-Mail	

Registration fee (Financial Management: CGC Management GmbH)

- 80 € (before March 01, 2014)  100 €  
 40 € Physician/Scientist in Training  20 € Student (with ID)  
 Participation in Gala Dinner March 14, 2014  Yes  No

I will pay by bank transfer.

Bank: Deutsche Kreditbank AG

Für die vertragliche und finanzielle Abwicklung dieser Veranstaltung zeichnet die Carl Gustav Carus Management GmbH verantwortlich.  
IBAN: DE 71 1203 0000 0011 248 333 · BIC: BYLADEM 1001

I will pay by credit card.

I authorize the charge of the registration fee.

VISA  MASTERCARD

Card No.: \_\_\_\_\_

Expiry date: \_\_\_\_/\_\_\_\_/\_\_\_\_ Cardholder: \_\_\_\_\_

Date: \_\_\_\_\_ Signature: \_\_\_\_\_



Antwort

Carl Gustav Carus Management GmbH  
Fetscherstraße 74  
01307 Dresden  
Germany